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Abstract
Protein conformational disorders are associated with the appearance, persistence, accumulation, and misprocessing of
aberrant proteins in the cell. The etiology of renal tubular dysgenesis (RTD) is linked to mutations in the angiotensin-
converting enzyme (ACE). Here, we report the identification of a novel ACE mutation (Q1069R) in an RTD patient. ACE
Q1069R is found sequestered in the endoplasmic reticulum and is also subject to increased proteasomal degradation,
preventing its transport to the cell surface and extracellular fluids. Modulation of cellular proteostasis by temperature shift
causes an extension in the processing time and trafficking of ACE Q1069R resulting in partial rescue of the protein
processing defect and an increase in plasma membrane levels. In addition, we found that temperature shifting causes the
ACE Q1069R protein to be secreted in an active state, suggesting that the mutation does not affect the enzyme’s catalytic
properties.
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Introduction
A growing number of human diseases, such as cystic fibrosis,
Alzheimer’s disease, and certain types of cancer, are associated
with alterations in the protein homeostasis network (proteostasis)
that lead to protein misfolding, mislocalization, or aggregation [1].
RTD is a severe disorder affecting renal tubular development
and is characterized by persistent fetal anuria and perinatal death
[2]. Mutations in different components of the renin-angiotensin
system have been linked to RTD, and one such class of mutations
are those found in the gene that codes for the angiotensin-
converting enzyme (ACE) [3]. In most cases, affected individuals
die in utero or within 24 hours of birth [2]. ACE is a zinc-
metallopeptidase and a key component of the renin-angiotensin-
aldosterone system involved in the regulation of blood pressure
and heart function through the formation of the vasoconstrictor
angiotensin II and inactivation of the vasodilator bradykinin [4,5].
ACE also regulates water balance, neuropeptide metabolism,
reproduction, immune functions and kidney development
[6,7,8,9]. There are two forms of ACE, a somatic and a testicular
form, both C-terminally anchored to the plasma membrane [10].
The somatic form is abundant in endothelial, epithelial and
neuronal cell membranes. Somatic ACE also exists as a soluble
form that originates from membrane-bound endothelial ACE by
the action of a yet unidentified protease. Soluble ACE is found in
the plasma, cerebrospinal fluid, seminal liquid, and urine [10,11],
and contains two enzymatic domains with a high degree of
internal sequence homology [12]. However, the active sites in the
two enzymatic domains display contrasting catalytic and immu-
nological properties and substrate specificities [13,14,15].
Recently, two novel homozygous mutations in the ACE gene
linked to autosomal recessive RTD were described [16,17]. Here,
we describe a novel point mutation in the ACE gene, encoding
ACE Q1069R, identified in a female RTD patient. We elucidated
the molecular mechanisms by which this mutation results in non-
functional ACE protein and discuss possible strategies for
therapeutic intervention in RTD and other disorders associated
with proteostasis network imbalance.
Results
Identification of the mutation in the ACE gene
In 2004, a female child was born by cesarean section after 36
weeks of gestation. Apgar score was 2 at the fist minute and 8 at
the tenth minute after birth. Somatometrics was adequate to the
gestational age. There was no history of parental consanguinity
and no reported cases of renal disease in the family. The mother
was a healthy young women and the pregnancy was uneventful,
with no reference to oligoamnious or to maternal drugs use. The
patient had a healthy older brother.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20854At birth, the patient presented large fontanels with widely
separated sutures, talus feet and joint contractures. Profound
hypotension recalcitrant to treatment with pressors was present
since the first hours after birth. She also presented moderate
respiratory distress and a persistent ductus arteriosus. Anuria was
detected at birth so peritoneal dialysis was started on the 3
rd day
after birth. The renal sonogram showed normal/high size kidneys,
with poor corticomedullary differentiation. The skull x-ray showed
poor ossification of the vault. Biochemical investigation indicated
very high plasmatic rennin (.1000 mcU/ml) and the karyotype
was normal (46 XX). Based on the above symptoms clinical
diagnosis of RTD was suspected. On the 12
th day pressor therapy
was stopped and she was transferred to the nephrology unit where
she was treated as an inpatient on continuous peritoneal dialysis
for 6 months. At that age, the patient started cycling peritoneal
dialysis and was discharged from the hospital. Diuresis slowly
increased until 1.5 ml/kg/day and the main problem was failure
to thrive with slight developmental retardation. At the age of 4
years the patient was successfully submitted to cadaver kidney
transplantation. She maintains normal graft function, improved
growth and normalized development.
Identification of the mutation in the ACE gene
Since ACE was previously implicated in RTD, we sequenced
the ACE gene from our patient and identified a homozygous A-to-
G nucleotide change in exon 22 (c.3293A.G) (Figure 1A). The
mutation caused a glutamine to arginine substitution at amino acid
1069 in the ACE protein. Segregation analysis in the family of the
proband showed that both of her clinically healthy parents and
one clinically healthy brother were heterozygous carriers for this
mutation. No other mutations were observed in the ACE gene
(Figure 1A).
Impact of the mutation on protein structure and activity
We assayed ACE activity from patient blood samples to
determine whether the mutation affected its enzymatic activity.
In contrast to the reported absence of activity prior to kidney
transplant [18], the patient displayed normal ACE activity
compared to five healthy volunteers (Figure S1). Lack of ACE
activity from the patient sample prior to kidney transplantation
may stem from changes in the active site of the mutant protein or
alternatively, the mutation may affect protein localization and
stability. In order to distinguish between these two possibilities we
employed molecular dynamics simulations of wild type (WT) and
mutant protein in a controlled environment. See SI for more
details about the molecular dynamics simulation. Root Mean
Squared Deviations (RMSD) of the amino-acids positions of WT
and mutant proteins, along with the simulation of the 3-D
structure, suggests that the Q1069R substitution should not
influence the structure of the active site (Figure 1B and Figure
S2). Amino acids comprising the active site of the enzyme and
residues involved in coordinating a Zn
2+ atom required for protein
activity showed little or no variation in RMSD in each protein,
suggesting that lack of activity is likely due to aberrant protein
processing (Figure S2). Moreover, molecular dynamics analysis
showed an increased exposed surface area in the mutated protein
caused by changes in the protein hydrodynamic radius (Figure S2),
consistent with an increase in the volume of internal pockets and
cavities present in the mutant protein relative to the WT protein
(Figure 1B).
Stability and cellular localization of the mutant ACE protein
In order to study ACE processing, we established a cellular
model to analyze localization, trafficking and turnover of WT and
mutant ACE. We generated stable cell lines expressing either WT
ACE (ACEWT) or ACE Q1069R (ACEQ1069R) in a human
embryonic kidney (HEK) cells. We performed immunoblot
analysis to investigate ACE protein levels both cell lines using an
anti-ACE antibody that recognizes the denatured form of the
protein (anti-ACE 1D8). ACE protein levels were approximately
80% lower in ACEQ1068R cells compared to ACEWT cells
Figure 1. Novel mutation in the ACE gene is associated with
RTD in a homozygous patient for the nucleotide substitution.
A. Mutation c.3293A.G (p.G1069R) in homozygous state in our
proband and in heterozygous state in the patient’s brother. Arrow
points the changing nucleotide. Wt: WT sequence of the ACE gene (part
of exon 22). On the bottom, pedigree of the family. Circles indicate
females; squares, males; filled symbols, affected individuals; open
symbols, unaffected individuals; Mut/Mut, homozygous p.Q1069R
mutation; Mut/WT, heterozygous Q1069R mutation (WT indicates WT
allele). B. Pocket and cavity analysis of C-terminal domains from native
ACE and Q1069R mutant after energy minimization of the atomic
coordinates and molecular dynamics simulations. Presence of pocket
and cavities within the structure were analyzed by POCASA algorithm
and the results plotted in 3D structure over the backbone of the native
ACE C-terminal domain atomic coordinates (PDB code: 2OC2). The
figure was prepared by using Pymol.
doi:10.1371/journal.pone.0020854.g001
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cells could be attributed to lower protein expression, decreased
protein stability, or both. To discriminate between these possi-
bilities, we performed quantitative RT-PCR analysis on ACEWT
and ACEQ1069R cells quantifying ACE mRNA levels and found no
significant difference between mRNA levels (Figure 2B). Thus, the
marked discrepancy between the mRNA and protein levels of wild
type and mutant ACE-expressing cells suggested reduced protein
stability for the mutant form. Next, we analyzed the half-life of
ACEWT and ACEQ1069R. Cells were treated with cyclohexamide
(CHX) to inhibit de novo protein synthesis and protein levels were
monitored by immunoblot analysis. While the ACEWT protein
showed essentially no decrease in protein levels over a 120 minutes
time course, ACEQ1069R protein is more rapidly degraded and is
not detected at 120 minutes, suggesting a decreased stability of the
mutant protein (Figure 2C).
To test whether the degradation of ACEQ1069R protein occurs
via the ubiquitin/proteasome system (UPS), we performed
immunoblot analysis in the presence of increasing concentrations
of the proteasome inhibitor ALLN. We observed a dose-
dependent increase in the level of mutant ACE protein suggesting
that the mutant form was degraded by the proteasome (Figure 2D).
These results indicate that the lower level of ACEQ1069R is due to
selective degradation of the mutant form by the UPS.
In order to investigate ACE’s cell surface localization, we
performed immunofluorescence analysis on both stable cell lines
using an antibody that recognizes the native form of the protein
(anti-ACE i2H5). Using non-permeabilizing conditions, we found
a well-defined membrane pattern in ACEWT cells, while
ACEQ1069R cells failed to show ACE protein on the cell surface
(Figure 3A). These results were confirmed by flow cytometry
(Figure 3B).
To assess whether the absence of plasma membrane localization
of the mutant protein was due to overall lower protein levels and/
or impairment in protein trafficking, the ACEQ1069R stable cell
line was treated with proteasome inhibitor and surface levels of
ACE were analyzed by flow cytometry and epifluorescence
microscopy. Although we detected an increase in ACEQ1069R
protein level in the presence of ALLN we could not observe any
increase in the level of the protein at the cell surface (Figure 3C),
suggesting that impaired protein trafficking caused the absence of
ACEQ1069R at the cell surface. Next, we analyzed the subcellular
localization of ACEWT and ACEQ1069R protein in stable cell lines
by epifluorescence microscopy. Immunofluorescence analysis
using the organelle markers calnexin, for the ER, and giantin,
for the Golgi, showed that approximately 80% of ACEQ1069R was
found in the ER, while only 10% of the WT protein was found in
the same compartment (Figure 3D). Furthermore, approximately
30% of WT and 10% of mutant protein were found in the Golgi,
implying impaired ER to Golgi trafficking of ACEQ1069R (Figure
S3). Taken together, these results suggest that mutant ACE is not
able to reach the plasma membrane, accumulates in the ER and,
as a consequence, is rapidly degraded by the proteasome. The
sequestration of ACEQ1069R in the ER suggests that it might be
misfolded.
Incubation of cells at 30uC increases the interaction of misfolded
proteins with molecular chaperones, facilitating their proper
folding and trafficking. Thus, we analyzed the subcellular
localization of ACEWT and ACEQ1069R by flow cytometry using
the i2H5 antibody and cells (non-permeabilized) grown at 30uC
for 4 days in order to determine if ACEQ1069R is misfolded. The
proportion of i2H5
+ cells in the population of ACEQ1069R cells
grown at 30uC increased 9-fold in contrast to cells grown at 37uC
(Figure 4A); WT ACE was not affected (Figure 4A). We confirmed
these results by fluorescence microscopy with ACEQ1069R and
ACEWT cells grown at 30uC for 4 days. ACEQ1069R cells grown at
30uC had more positively stained cells compared to cells grown at
37uC (Figure 4B). We examined ACE protein levels at the two
different temperatures in order to exclude the possibility that the
rescue of mutant ACE localization to the plasma membrane at
30uC was due to alteration in protein levels. Cells grown at 30uC
did not affect protein levels of either WT or mutant proteins as
compared to 37uC (Figure S4). Since growing cells at 30uC can
augment the amount of the mutant protein present at the plasma
membrane and this effect is not increased in the presence of
Figure 2. Low ACEQ1069R protein levels in HEK cells is due to
degradation by the ubiquitin proteasome system. A. Analysis of
ACE protein levels by western blot in HEK cells stably expressing the WT
form or the mutant (Q1069R). Empty vector is used as a negative
control. GAPDH was used as a loading control. Quantification of 3
independent experiments is shown on the right. Error bars represent
6SD. P,0.05. B. Relative quantitative analysis of ACE mRNA levels in
HEK cells stably expressing WT or ACEQ1069R, normalized to b-actin. Error
bar represents 6SD. C. Analysis of ACE protein stability by pulse-chase
experiment in HEK cells. Cells were treated with CHX, for the indicated
times. Protein levels were assessed by western blot analysis. Quanti-
fication of 3 independent experiments is shown. Error bars represent
6SD. P,0.05. D. Western blot analysis of ACEQ1069R HEK cells. Cells in
growth medium were treated for 2h with control medium or media
with increasing dosages of ALLN. On the right, quantification of three
independent experiments is shown. Error bars represent 6SD. P,0.05.
doi:10.1371/journal.pone.0020854.g002
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the ER to Golgi was rescued at 30uC. To test this, HEK cells
stably expressing ACEQ1069R or ACEWT were permeabilized and
stained with anti-ACE i2H5 antibody and markers for calnexin
and giantin; cells were then visualized by confocal microscopy
(Figure 4C and Figure S5). Interestingly, there was an increase in
co-localization of ACEQ1069R with the Golgi, suggesting an
improvement in ACE protein trafficking from the ER to Golgi
(Figure 4C and Figure S5) resulting in partially restored surface
expression of the mutant protein. Our results suggest that the point
mutation in ACE gene is responsible for protein misfolding and
retention in the ER leading to its degradation by the UPS;
moreover, this defect can be partially overcome by growing cells at
30uC. To further confirm our findings we blocked protein
trafficking through the secretory pathway using Brefeldin A
(BFA) and tunicamycin. BFA interferes with protein transport
from the ER to the Golgi apparatus, while retrograde transport
from the Golgi to the ER stays unaffected, resulting in the partial
redistribution of the Golgi resident protein to the ER. Further-
more, BFA also affects Golgi stacking, leading to dispersion of the
Figure 3. ACEQ1069R protein is sequestered intracellular and does not reach the plasma membrane. A. HEK cells plated on glass cover
slips for 2 days then fixed and not permeabilized and immunostained for ACE (green). Immunofluorescence staining observed by confocal
microscopy. Scale bars, 20 mm. B. Analysis of ACE protein by flow cytometry in non-permeabilized ACEWT and ACEQ1069R stable cells. Quantification of
3 independent experiments is shown. Error bars represent 6SD. P,0.05. C. Analysis of ACE protein by flow cytometry in non-permeabilized ACEWT
and ACEQ1069R stable cells grown in the presence of ALLN or control media for 2h. Quantification of 3 independent experiments. Error bars represent
6SD. D. HEK cells plated on glass cover slips for 2 days then fixed and immunostained for ACE (green), ER (red) and nuclei are stained blue with
DAPI). Immunofluorescence staining observed with confocal microscopy. Insets represent enlarged images in the boxed regions. Scale bars, 20 mm.
Quantification of the green signal overlapping with red signal was done using ImageJ software.
doi:10.1371/journal.pone.0020854.g003
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membrane. Tunicamycin is an inhibitor of N-linked protein
glycosylation affecting protein folding in the ER, which leads to an
increase in ER protein retention time. If rescue at 30uC is indeed
due to facilitated trafficking through the secretory pathway,
treatment of cells with these drugs should oppose the rescue
effect. Indeed, treatment of ACEQ1069R cells with BFA and
tunicamycin at 30uC, resulted in 50% lower protein surface
expression as observed by immunofluorescence (Figure 5A).
Moreover, tunicamycin decreased ACEQ1069R colocalization with
Golgi markers while BFA showed no colocalization and caused
dispersion of the organelle (Figure 5B). Our results indicate that
impaired trafficking through the secretory pathway causes reduced
plasma membrane levels of ACEQ1069R protein.
Figure 4. ACEQ1069R in the plasma membrane at 306C due to an improvement of trafficking through the secretory pathway. A. Flow
cytometry analysis of ACE protein levels at the plasma membrane in non-permeabilized cells. ACEQ1069R and ACEWT HEK cells grown at 37uCo r3 0 uC
for 4 days. Quantification of 3 independent experiments. Error bars represent 6SD. P,0.05. B. Immunostain analysis by confocal microscopy of
ACEQ1069R HEK cells grown in glass coverslips at 37uC versus 30uC for 4 days. Cell not permeabilized and fixed were stained with ACE in green, nuclei
are stained blue with DAPI. Scale bars, 20 mm. C. Same conditions and cells as in A. Cells were permeabilized and double stained for Golgi (red) and
ACE (green). Nuclei are stained blue with DAPI. Insets represent enlarged images in the boxed regions. Scale bars, 20 mm. Quantification of the green
signal overlapping with red signal was done using ImageJ software.
doi:10.1371/journal.pone.0020854.g004
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ACEQ1069R is not able to reach its proper localization at the
plasma membrane due to impaired trafficking (Figure 3A and D). We
hypothesized that, once ACEQ1069R reaches the cell surface, the
mutant protein will be secreted into the extracellular fluids and its
activity should be restored; this hypothesis is further supported by the
modelingofthe3-DstructureoftheACEprotein,whichsuggeststhat
the ACEQ1069R point mutation should not affect the enzymatic
activity of the protein (Figure 1B). To directly test our hypothesis,
media from ACEQ1069R and ACEWT cells grown at 30uCf o r4d a y s
were harvested and tested by western blot and for ACE activity
(Figure 6A and B). Interestingly, in the ACEQ1069R cells ACE activity
doubled when cells were grown at 30uC (Figure 6B), indicating that
higher ACE levels at the plasma membrane and in the media is
coupled with increased enzymatic activity in the media. In summary,
o u rr e s u l t ss u g g e s tt h a ti ft h eA C E Q1069R mutant protein reaches its
proper localization in the cell, it will be secreted to the extracellular
fluids where it can perform its normal function.
Discussion
The correct expression, folding, trafficking and processing of
proteins is essential for the overall cellular homeostasis and is
emerging as a novel concept known as proteostasis [19]. However,
the precise and intricate ways through cells regulate proteostasis
are not fully understood, complicating the development of
therapeutic strategies for several human disorders. Importantly,
a recent study highlighted the potential of proteostasis modulation
for the treatment of human diseases, showing that guanabenz, a
small molecule used in hypertension treatments, rescued cells from
protein misfolding stress due to elevated chaperone availability
leading to improved folding [20].
We identified a novel mutation in the ACE gene responsible for
autosomal RTD, a disorder that usually results in premature
death, and characterized the molecular defects associated with the
identified mutation.
A major challenge in the study of RTD was overcome by the
development of an in vitro model which enabled us to demonstrate
that a single amino acid substitution in the C-terminal domain of
ACE causes the retention of the protein in the ER, degradation by
the UPS, and altered trafficking, resulting in decreased presence
on the plasma membrane. The trafficking of proteins from the ER
is regulated by several critical and distinct mechanisms. First,
quality control pathways ensure that only properly folded proteins
are allowed to exit the ER [21]. Chaperone proteins within the ER
participate in both protein folding and the retention of misfolded
Figure 5. BFA and tunycamicin abolishes the 306C rescue of ACEQ1069R at the plasma membrane. A. Immunostaining analysis by
confocal microscopy of ACEQ1069R HEK cells grown at 30uC on glass coverslips in the presence of 10 mg/ml Tunycamicin for 6h, 10 mg/ml BFA for 6h or
control media. Cells were not permeabilized and stained with ACE (green). Scale bars, 20 mm. Quantification of number of cell which display ACE
membrane signal. Quantification of 3 independent experiments. Error bars represent 6SD. B. Immunostain analysis by confocal microscopy of
ACEQ1069R HEK cells grown in the same conditions as in A. Cells were fixed, permeabilized, stained for ACE (green) and Golgi (red). Nuclei are stained
blue with DAPI. Insets represent enlarged images in the boxed regions. Scale bars, 20 mm. Quantification of the green signal overlapping with red
signal was done using ImageJ software. Quantification of 3 independent experiments. Erros bars represent 6SD.
doi:10.1371/journal.pone.0020854.g005
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are eliminated via the UPS system, in a process known as ERAD
[23]. Thus, one possibility is that ACEQ1069R protein misfolds due
to the substitution of a neutral amino acid by a positively charged
residue, altering folding kinetics. Both protein modeling and the
observation that mutated ACE is present in low levels in the cell
and is degraded by the proteasome support this theory.
Alternatively, since ACE is composed of two similar domains, it
may form intermediate dimers that are transport-competent to
leave the ER and travel to the Golgi. Analysis of the quaternary
structure of several membrane and secreted proteins supports the
idea that dimer or oligomer formation is an important event that
affects the rate of transport of proteins from the ER to the Golgi
[24,25].
Several disorders are caused the inability of a mutant protein to
properly travel through the secretory pathway [26] including
bilateral frontoparietal polymicrogyria and cystic fibrosis [27,28].
In cystic fibrosis, the most common mutation in cystic fibrosis
transmembrane conductance regulator (CFTR) leads to its
retention in the ER and degradation by the UPS [29]; interfering
with chaperone activity can prevent ER-sequestration, resulting in
restored transport to the plasma membrane [30]. Incubation of
cells at low temperature can have similar biological effects in cells
with mutant CFTR, where low temperature enables the proper
folding and maturation of the protein [31]. Similarly, localization
of ACE at the plasma membrane was restored when we modulated
the proteostasis network by growing cells at a lower temperature.
Under these conditions the catalytic activity of the mutant protein
was also restored suggesting that the mutation did not directly
affect protein activity. When traffic through the secretory pathway
was inhibited by BFA and tunicamycin, the mutant protein was
unable to reach plasma membrane and no activity in the media
was detected, confirming that the functional defect in mutant ACE
activity was a consequence of aberrant protein trafficking rather
than the loss of enzymatic activity.
Recently, it was shown that elevated levels of ACE expression is a
risk factor in several cardiovascular and renal diseases and that
overexpression of ACE is observed in breast, lung, and gastric
cancer [32,33,34]; therefore, understanding the mechanism of ACE
regulation is an important goal not only for the basic understanding
of ACE biology, but also for clinical practice. Our work has several
important consequences: first, it provides important insights into
the functional structure of ACE; and secondly, it provides new
information about the mechanism through which ACE mutations
can lead to the severe cases of RTD.
Materials and Methods
Constructs and Cell Lines
HEK cells were a king gift from Dr. Luis Moita. Cells were in
DMM supplemented with 10% heat inactivated fetal bovine
serum, penicillin, streptomycin and L-Glutamine.
ACEQ1069R was generated by site directed mutagenesis from the
pCDNA3.1-Hygro-ACEWT(kindlyprovided byDr.SergeiDanilov).
Site directed mutagenesis was performed as recommended with
the QuickChange XL Site Directed Mutagenesis Kit (Stratagene).
The CAG codon (glutamine) was mutated to a CGG codon
(arg) at position 1069 using the forward primer: 59-ggctgaag-
taccggggcctctgccc-39 and the reverse primer: 59-gggcagaggccccgg-
tacttcagcc-39. The resulting construct was verified by sequencing.
Immunoblot and Antibodies
Cells were washed with cold PBS, and lysed with NP-40 buffer
in the presence of protease inhibitor cocktail (Roche). Lysates were
Figure 6. ACEQ1069R activity is normal in HEK cells at 306C. A. Western blot analyses of media from ACEWT and ACEQ1069R HEK cells grown at
37uC and 30uC. Equal amounts of total protein were loaded. Quantification of 3 independent experiments. Error bars represent 6SD. P,0.05. B. ACE
activity in the media from ACEQ1069R HEK cells grown at 37uC and 30uC. Activity was determined with a synthetic substrate (HHL) for 15 minutes
incubation Activity was normalized by the amount of protein present in the media (quantification in A, using arbitrary units).
doi:10.1371/journal.pone.0020854.g006
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total protein was quantified by Bradford Assay Kit (Biorad). Equal
amounts of total protein were subjected to SDS-PAGE using 10%
Tris–Glycine gel. Proteins on the SDS-PAGE were transferred to
PVDF membranes(Biorad)and blocked inblockingbuffer (5% milk
in TBS with 0.1% Tween-20: TBS-T, pH 7.4) for 1h prior to the
addition of the primary antibody overnight at 4uC. Primary
antibodies: anti-ACE 1:1000 (1D8) and anti-GAPDH 1:5000
dilution (Ambion). Blots were washed three times with TBS-T
and incubated at room temperature for 1h in HRP labeled
secondary antibodies (GE Healthcare, 1:10000 dilution).After three
washes with TBS-T, immunoblots were developed using ECL
(Millipore). The films were scanned and quantified with ImageJ.
Molecular dynamics simulations
All simulations were performed with the GROMACS package
and the all atom GROMOS96 force field. Presence of pocket and
cavities within the structure were analyzed by POCASA
algorithm. The atomic coordinates of ACE C-terminal domain
from testis (PDB code: 2OC2) were used as initial model for the
simulations. All the simulations were started with the aminoacid
side chain conformations extracted from the PDB database with a
protonation state consistent with a neutral pH. Proteins were
solvated in a water box of 110 A ˚ 3 and a density of 1 g/cm3. The
solvated models were energy minimized by conjugated gradient
for 1000 steps to eliminate steric clashes between atoms. All the
systems were equilibrated by simulated annealing with slow
temperature decreasing from 2500 K to 300 K over 1000 cycles.
Molecular dynamics simulations were then performed over 400 ps
at 300 K and data collected every 1 ps.
Flow cytometry analysis
HEK cells stably expressing ACEWT and ACEQ1069R were
washed with ice cold PBS, detached with 1mM EDTA in PBS,
resuspended in 0.5% BSA in PBS and stained with primary
antibody (i2H5) for 20 min. After washing cells, cells were
incubated with secondary antibody, alexa 488 anti-mouse, for
20 min. Acquisition was done on a FACS Calibur cytometer and
analysis was performed with the FlowJo software.
Immunocytochemistry and Fluorescence microscopy
Cells were plated in 12-well plates on a glass coverslip coated
with poly-d-lysine (Sigma), grown at the corresponding tempera-
tures (37uCo r3 0 uC). We added Brefeldin A at 10 mg/ml for 6h
and tunicamycin at 10 mg/ml for 6 h. Cells were fixed in 4%PFA
for 10 min, permeabilized with 0.5% Triton-100 in TBS and
blocked for 1h with 1.5% goat serum. Primary antibodies were:
anti-ACE 2iH5, anti-Calnexin antibody (1:100 dilution; Invitro-
gen), and giantin (1:250 dilution, ABCAM). Alexa 488 and Alexa
568 conjugated secondary antibodies were used at a 1:1000
dilution. Coverslips were mounted with Vectashield and visualized
on a Zeiss LSM 510 META confocal microscope using a 63x/1.4
oil immersion objective. Sequential multi-track frames were
acquired to avoid any potential crosstalk from the two fluor-
ophores. Quantification of co-localization was performed in
ImageJ (http://rsbweb.nih.gov/ij/). For details see SI.
Real time PCR
Total RNA was extracted using Trizol reagent according to the
manufacturer (Invitrogen). cDNA was synthesized from 4 mg total
RNA using random primers and superscript II reverse transcrip-
tase following the manufacturer instructions (Invitrogen). Real
time PCR was performed using SYBR green master mix
according to the manufacturer manual (Sigma Aldrich). All
reactions were performed in triplicates. PCR primers were specific
for ACE (GGT GGT GTG GAA CGA GTA TG, TCG GGT
AAA ACT GGA GGA TG) and b-actin. Quantification was done
in following the Pfaffl method.
In vivo Protein Stability Assay
HEK cells stably expressing ACEWT or ACEQ1069R were grown
in the presence of 10uM Cyclohexamide (CHX) and either
ethanol or 10uM ALLN (N-acetyl-L-leucyl-L-leucyl-L-norleucine)
(both from Sigma), cells were harvest at each time point and lysates
were analyzed by western blot. The films were scanned and
quantified with ImageJ.
Enzymatic Activity
Media in which stable cells were grown was collected (10ml per
10cm dish) and concentrated using a Vivaspin-15R column
following manufacture instruction (Sartorius stedim). BCA was
used to quantify total protein in 10X concentrated media. For ACE
activity in the blood, a peripheral blood sample using standard
procedures was extracted from patient and 5 healthy volunteers.
Written informed consent was obtained from all of the participants
according to the Declaration of Helsinki, and the study was
approved by the ethics committee of the Hospital de Santa Maria,
Lisbon, Portugal. ACE colorimetric enzymatic assay was performed
according to the manufacturer (Buhlmann). Briefly, equal amount
of total protein from the media were added to 300 ml of incubation
buffer and 200 ml substrate (HHL) for 15 min at 37uC. The product
was quantified by measuring emission wavelength at 382nm.
Sequencing
Genomic DNA of the patient, his parents and brother were
extractedfromaperipheralbloodsampleusingstandardprocedures.
Written informed consent was obtained from all of the participants
according to the Declaration of Helsinki, and the study was
approved by the ethics committee of the Hospital de Santa Maria,
Lisbon, Portugal. The ACE gene was analyzed for mutations.
Intronic primers that flank each of the 26 ACE exons were used
(GenBank accession number NM_000789) for sequencing. PCRs
were performed with 100 ng template of genomic DNA denatured
for5 minat94
oCfollowedby30cyclesofamplification(45sat95
oC;
45s at specific annealing temperature; 45 s at 72uC) followed by a
10 min extension of 72uC. PCR products were tested on a 2%
agarose gel. PCR products were sequenced on an automated
sequencer ABI PRISMR 3100-Avant using a BigDye v3.1 sequence
kit (Applied Biosystems) and analysis was done on both strands of the
PCR amplified exons whenever a mutation was found.
Supporting Information
Figure S1 ACE activity in the plasma from the RTD patient
and 5 controls healthy volunteers (marked 1 to 5) using a synthetic
substrate (HHL) for15 minutes incubation.
(TIF)
Figure S2 Evolution of average RMSD of each aminoacid and
overall hydrodynamic properties of ACE C-terminal domain wild
type and Q1069R mutant during the moleculardynamics
simulation. Parameters along the simulation were represented by
black lines for ACE WT protein and by red lines for ACE
Q1069Rmutant. Panels A: aminoacid average RMSD along the
simulation. The upper scheme represents the relative position of
the aminoacids belonging to the active site of the enzyme and
involved in the coordination of the Zn2+atom and the location of
Impaired Proteostasis in RTD
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20854the characterized Q1069R mutation; Panels A: hydrophobic
solvent accessible surface; B: hydrophobic solvent accessible
surface; C: hydrophilic solvent accessible surface; D: total solvent
accessible surface; E: Rx hydrodynamic radius; F: Ry hydrody-
namic radius and G: Rz hydrodynamic radius.
(TIF)
Figure S3 Immunostain analysis by confocal microscopy of
ACEQ1069R and ACEWT cells grown at 37uC on glass coverslips.
Cell were fixed and permeabilized, then double stained for ACE
(green) and Golgi (red). Nuclei are stained blue with DAPI. Inset
represent enlarged images in the boxed regions. Scale bars, 20 mm.
Quantification of the green signal overlapping with red signal was
done using ImageJ software. Quantification of 3 independent
experiments. Error bars represent 6SD. P,0.05.
(TIF)
Figure S4 Western blot analysis of ACE protein levels in
ACEQ1069R and ACEWT cells. Cells were grown at 37uCo r3 0 uC
for 4 days. Quantification of 3 independent experiments. Error
bars represent 6SD.
(TIF)
Figure S5 Immunostaining analysis by confocal microscopy of
ACEQ1069R cells grown at 37uCo r3 0 uC for 4 days on glass
coverslips. Cell were fixed and permeabilized, then double stained
for ACE (green) and ER (red). Nuclei are stained blue with DAPI.
Inset represents enlarged images in the boxed regions. Scale bars,
20 mm.
(TIF)
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